Aldeyra launches multiple mid-stage trials to evaluate ADX-629

 

• Aldeyra Therapeutics (NASDAQ:ALDX) has initiated Phase 2 trials of ADX-629, a reactive aldehyde species inhibitor, for the treatment of COVID-19, atopic asthma, and psoriasis as part of a systematic strategy to assess activity across different types of immunological diseases.
• In April, it disclosed Phase 1 data in 85 healthy volunteers that showed ADX-629 was well-tolerated with no treatment-related adverse events observed with clinically relevant plasma concentrations. Reductions in pro-inflammatory RASP malondialdehyde was noted in treated participants.
• COVID-19 Phase 2 will evaluate the safety, tolerability, efficacy, and pharmacodynamics of ADX-629 in ~30 adult patients. The FDA signed off the study in September, and enrollment is expected to begin by year-end.
• Atopic Asthma Phase 2 trial in 12 subjects, outcomes will include pulmonary function testing following allergen and methacholine challenge, sputum eosinophil counts, and plasma levels of cytokines and RASP. Enrollment is expected to begin in Q1 of 2021.
• Psoriasis study in 10 patients will evaluate severity index, skin cytokine transcription profiles, plasma leukocyte cytokine release following endotoxin-challenge, and plasma levels of cytokines and RASP. Enrollment is expected to begin 1H of 2021.
• https://seekingalpha.com/news/3645328-aldeyra-launches-multiple-mid-stage-trials-to-evaluate-adxminus-629